



Confirmation of HLA Typing

Registry Use Only

Sequence Number:

Date Received:

OMB No: 0915-0310

Expiration Date: 09/30/2028

Public Burden Statement: The purpose of this data collection system is to provide technical assistance and share expertise with health care organizations, health care providers and health care networks interested in implementing telehealth technology. The resource centers serve as focal points for advancing the effective use of telehealth technologies in their respective communities and regions. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this information collection is 0915-0310 and it is valid until 09/30/2028. Public reporting burden for collection of information cumulative for this and all other relevant collection instruments for the procedure and product information timepoint is estimated to average 0.75 hours per response, including the time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 14N136B, Rockville, Maryland, 20857 or paperwork@hrsa.gov.

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Event date: _____

YYYY

MM

DD

Product Identifiers:

Registry donor ID: _____

Non-NMDP cord blood unit ID: _____

Global Registration Identifier for Donors (GRID): _____

Registry or UCB Bank ID: _____

Donor DOB: _____ - _____ - _____

YYYY

MM

DD

Donor age: ____ ☐ Months (use only if less than 1 year old)

☐ Years

Donor sex ☐ Male ☐ Female

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Donor / Cord Blood Unit Identification

This form must be completed for all recipients, related donors (except Syngeneic & HLA-Identical), non-NMDP allogeneic donors, or non-NMDP cord blood units. If the donor or cord blood unit was secured through the NMDP and the recipient has an NMDP RID, then report HLA typing on the appropriate NMDP forms.

Minimum required typing: HLA-A, -B, -C, -DRB1. Optimum: HLA-A, -B, -C, -DRB1, -DRB3/4/5, -DQA1, -DQB1, -DPA1 and -DPB1

A separate copy of this form should be completed for the recipient and each non-NMDP donor or cord blood unit.

1. Specify the person for whom this typing is being done

☐ Recipient — final typing

☐ Donor

HLA Typing by DNA Technology

CIBMTR strongly encourages attaching the HLA laboratory report.

Class I

2. Locus A

☐ Known – **Go to question 3**

☐ Unknown – **Go to question 4**

3. First A* allele designations: _____

Second A* allele designations: _____

4. Locus B

☐ Known – **Go to question 5**

☐ Unknown – **Go to question 6**

5. First B* allele designations: _____

Second B* allele designations: _____

6. Locus C

☐ Known – **Go to question 7**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

☐ Unknown – **Go to question 8**

7. First C* allele designations: _____

Second C* allele designations: _____

Class II

8. Locus DRB1

☐ Known – **Go to question 9**

☐ Unknown – **Go to question 10**

9. First DRB1* allele designations: _____

Second DRB1* allele designations: _____

10. Locus DRB3

☐ Known – **Go to question 11**

☐ Unknown – **Go to question 12**

11. First DRB3* allele designations: _____

Second DRB3* allele designations: _____

12. Locus DRB4

☐ Known – **Go to question 13**

☐ Unknown – **Go to question 14**

13. First DRB4* allele designations: _____

Second DRB4* allele designations: _____

14. Locus DRB5

☐ Known – **Go to question 15**

☐ Unknown – **Go to question 16**

15. First DRB5* allele designations: _____

Second DRB5* allele designations: _____

16. Locus DQB1

☐ Known – **Go to question 17**

☐ Unknown – **Go to question 18**

CIBMTR Center Number: _____ CIBMTR Research ID: _____

17. First DQB1* allele designations: _____

Second DQB1* allele designations: _____

18. Locus DPB1

☐ Known – **Go to question 19**

☐ Unknown – **Go to question 20**

19. First DPB1* allele designations: _____

Second DPB1* allele designations: _____

20. Locus DQA1

☐ Known – **Go to question 21**

☐ Unknown – **Go to question 22**

21. First DQA1* allele designations: _____

Second DQA1* allele designations: _____

22. Locus DPA1

☐ Known – **Go to question 23**

☐ Unknown – **Go to question 24**

23. First DPA1* allele designations: _____

Second DPA1* allele designations: _____

Antigens Defined by Serologic Typing

Use the following lists when reporting HLA-A and B antigens. Report broad antigens only when your laboratory was not able to confirm typing for a known split antigen.

Instructions for the use of the “X” Antigen Specificity for Typing By Serology

Each HLA locus has a serologically defined “X” antigen specificity: AX, BX, CX, DRX, DPX, and DQX. At this time an “X” specificity is defined as “unknown but known to be different from the other antigen at that locus.” This is different from a blank specificity, which is defined as “unknown but assumed to be the same as the other antigen at that locus.”

A Antigens

24. Number of antigens provided

CIBMTR Center Number: _____

CIBMTR Research ID: _____

☐ One – **Go to question 25, then continue with question 27**

☐ Two – **Go to questions 25-26**

25. Specificity – 1st antigen

- ☐ A1
- ☐ A2
- ☐ A203
- ☐ A210
- ☐ A3
- ☐ A9
- ☐ A10
- ☐ A11
- ☐ A19
- ☐ A23(9)
- ☐ A24(9)
- ☐ A2403
- ☐ A25(10)
- ☐ A26(10)
- ☐ A28
- ☐ A29(19)
- ☐ A30(19)
- ☐ A31(19)
- ☐ A32(19)
- ☐ A33(19)
- ☐ A34(10)
- ☐ A36
- ☐ A43
- ☐ A66(10)
- ☐ A68(28)
- ☐ A69(28)
- ☐ A74(19)
- ☐ A80
- ☐ AX

26. Specificity – 2nd antigen

- ☐ A1
- ☐ A2

CIBMTR Center Number: _____

CIBMTR Research ID: _____

- ☐ A203
- ☐ A210
- ☐ A3
- ☐ A9
- ☐ A10
- ☐ A11
- ☐ A19
- ☐ A23(9)
- ☐ A24(9)
- ☐ A2403
- ☐ A25(10)
- ☐ A26(10)
- ☐ A28
- ☐ A29(19)
- ☐ A30(19)
- ☐ A31(19)
- ☐ A32(19)
- ☐ A33(19)
- ☐ A34(10)
- ☐ A36
- ☐ A43
- ☐ A66(10)
- ☐ A68(28)
- ☐ A69(28)
- ☐ A74(19)
- ☐ A80
- ☐ AX

B Antigens

27. Number of antigens provided

- ☐ One – **Go to question 28, then continue with question 30**
- ☐ Two – **Go to questions 28-29**

28. Specificity – 1st antigen

- ☐ B5
- ☐ B7

CIBMTR Center Number: ____

CIBMTR Research ID: ____

- ☐ B703
- ☐ B8
- ☐ B12
- ☐ B13
- ☐ B14
- ☐ B15
- ☐ B16
- ☐ B17
- ☐ B18
- ☐ B21
- ☐ B22
- ☐ B27
- ☐ B2708
- ☐ B35
- ☐ B37
- ☐ B38(16)
- ☐ B39(16)
- ☐ B3901
- ☐ B3902
- ☐ B40
- ☐ B4005
- ☐ B41
- ☐ B42
- ☐ B44(12)
- ☐ B45(12)
- ☐ B46
- ☐ B47
- ☐ B48
- ☐ B49(21)
- ☐ B50(21)
- ☐ B51(5)
- ☐ B5102
- ☐ B5103
- ☐ B52(5)
- ☐ B53
- ☐ B54(22)

CIBMTR Center Number: ____

CIBMTR Research ID: ____

- ☐ B55(22)
- ☐ B56(22)
- ☐ B57(17)
- ☐ B58(17)
- ☐ B59
- ☐ B60(40)
- ☐ B61(40)
- ☐ B62(15)
- ☐ B63(15)
- ☐ B64(14)
- ☐ B65(14)
- ☐ B67
- ☐ B70
- ☐ B71(70)
- ☐ B72(70)
- ☐ B73
- ☐ B75(15)
- ☐ B76(15)
- ☐ B77(15)
- ☐ B78
- ☐ B81
- ☐ B82
- ☐ BX

29. Specificity – 2nd antigen

- ☐ B5
- ☐ B7
- ☐ B703
- ☐ B8
- ☐ B12
- ☐ B13
- ☐ B14
- ☐ B15
- ☐ B16
- ☐ B17

CIBMTR Center Number: ____

CIBMTR Research ID: ____

- ☐ B18
- ☐ B21
- ☐ B22
- ☐ B27
- ☐ B2708
- ☐ B35
- ☐ B37
- ☐ B38(16)
- ☐ B39(16)
- ☐ B3901
- ☐ B3902
- ☐ B40
- ☐ B4005
- ☐ B41
- ☐ B42
- ☐ B44(12)
- ☐ B45(12)
- ☐ B46
- ☐ B47
- ☐ B48
- ☐ B49(21)
- ☐ B50(21)
- ☐ B51(5)
- ☐ B5102
- ☐ B5103
- ☐ B52(5)
- ☐ B53
- ☐ B54(22)
- ☐ B55(22)
- ☐ B56(22)
- ☐ B57(17)
- ☐ B58(17)
- ☐ B59
- ☐ B60(40)
- ☐ B61(40)
- ☐ B62(15)

CIBMTR Center Number: _____

CIBMTR Research ID: _____

- ☐ B63(15)
- ☐ B64(14)
- ☐ B65(14)
- ☐ B67
- ☐ B70
- ☐ B71(70)
- ☐ B72(70)
- ☐ B73
- ☐ B75(15)
- ☐ B76(15)
- ☐ B77(15)
- ☐ B78
- ☐ B81
- ☐ B82
- ☐ BX

Optional Antigen Reporting

Please provide the following optional antigen information if it is available from your laboratory.

Antigens Defined by Serologic Typing

C Antigens

30. Number of antigens provided

- ☐ One – **Go to question 31, then continue with question 33**
- ☐ Two – **Go to questions 31-32**

31. Specificity – 1st antigen

- ☐ Cw1
- ☐ Cw2
- ☐ Cw3
- ☐ Cw4
- ☐ Cw5
- ☐ Cw6
- ☐ Cw7
- ☐ Cw8
- ☐ Cw9(w3)

CIBMTR Center Number: _____

CIBMTR Research ID: _____

☐ Cw10(w3)

☐ CX

32. Specificity – 2nd antigen

☐ Cw1

☐ Cw2

☐ Cw3

☐ Cw4

☐ Cw5

☐ Cw6

☐ Cw7

☐ Cw8

☐ Cw9(w3)

☐ Cw10(w3)

☐ CX

Bw Specificity

33. Specificity Bw4 present?

☐ Yes

☐ No

34. Specificity Bw6 present?

☐ Yes

☐ No

DR Antigens

35. Number of antigens provided

☐ One – **Go to question 36, then continue with question 38**

☐ Two – **Go to questions 36-37**

36. Specificity – 1st antigen

☐ DR1

☐ DR103

☐ DR2

☐ DR3

☐ DR4

☐ DR5

CIBMTR Center Number: _____

CIBMTR Research ID: _____

- ☐ DR6
- ☐ DR7
- ☐ DR8
- ☐ DR9
- ☐ DR10
- ☐ DR11(5)
- ☐ DR12(5)
- ☐ DR13(6)
- ☐ DR14(6)
- ☐ DR1403
- ☐ DR1404
- ☐ DR15(2)
- ☐ DR16(2)
- ☐ DR17(3)
- ☐ DR18(3)
- ☐ DRX

37. Specificity – 2nd antigen

- ☐ DR1
- ☐ DR103
- ☐ DR2
- ☐ DR3
- ☐ DR4
- ☐ DR5
- ☐ DR6
- ☐ DR7
- ☐ DR8
- ☐ DR9
- ☐ DR10
- ☐ DR11(5)
- ☐ DR12(5)
- ☐ DR13(6)
- ☐ DR14(6)
- ☐ DR1403
- ☐ DR1404
- ☐ DR15(2)

CIBMTR Center Number: _____

CIBMTR Research ID: _____

☐ DR16(2)

☐ DR17(3)

☐ DR18(3)

☐ DRX

DR51 Antigen

38. Specificity DR51 present?

☐ Yes

☐ No

DR52 Antigen

39. Specificity DR52 present?

☐ Yes

☐ No

DR53 Antigen

40. Specificity DR53 present?

☐ Yes

☐ No

DQ Antigens

41. Number of antigens provided

☐ One – **Go to question 42, then continue with question 44**

☐ Two – **Go to questions 42-43**

42. Specificity – 1st antigen

☐ DQ1

☐ DQ2

☐ DQ3

☐ DQ4

☐ DQ5(1)

☐ DQ6(1)

☐ DQ7(3)

☐ DQ8(3)

CIBMTR Center Number: _____

CIBMTR Research ID: _____

☐ DQ9(3)

☐ DQX

43. Specificity – 2nd antigen

☐ DQ1

☐ DQ2

☐ DQ3

☐ DQ4

☐ DQ5(1)

☐ DQ6(1)

☐ DQ7(3)

☐ DQ8(3)

☐ DQ9(3)

☐ DQX

DP Antigens

44. Number of antigens provided

☐ One – **Go to question 45, then continue end of form**

☐ Two – **Go to questions 45-46**

45. Specificity – 1st antigen

☐ DPw1

☐ DPw2

☐ DPw3

☐ DPw4

☐ DPw5

☐ DPw6

☐ DPX

46. Specificity – 2nd antigen

☐ DPw1

☐ DPw2

☐ DPw3

☐ DPw4

☐ DPw5

☐ DPw6

CIBMTR Center Number: ____

CIBMTR Research ID: ____

☐ DPX